{"entity":{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","aka":[],"tldr":"Valink designs antibody-drug conjugates that grab two targets at once, aimed at solid tumours that immunotherapy does not reach.","summary":"Valink Therapeutics discovers next-generation antibody-based therapeutics by combining multiple modifications, bispecificity, multivalency and payload conjugation, in a single discovery workflow, generating bispecific antibody-drug conjugates from known tumour targets with new mechanisms of action. Its stated focus is solid tumours poorly served by immunotherapy. Programmes are preclinical as far as public sources show; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/valink-therapeutics"},{"label":"Official website","url":"https://www.valinktx.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["bispecific-adc","adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.valinktx.com","stage":"startup","ycBatch":"W21","investors":["y-combinator"],"funding":[]},"route":"/companies/valink-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}